Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first

Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.

Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.